PIERIS PHARMACEUTICALS, INC. Quarterly Debt-to-equity in % from Q3 2015 to Q4 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Pieris Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2015 to Q4 2023.
  • Pieris Pharmaceuticals, Inc. Debt-to-equity for the quarter ending December 31, 2023 was 137 %, a 22.5% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2023 137 -39.6 -22.5% Dec 31, 2023
Q3 2023 184 +10.3 +5.95% Sep 30, 2023
Q2 2023 205 +23.4 +12.9% Jun 30, 2023
Q1 2023 217 +18.9 +9.55% Mar 31, 2023
Q4 2022 176 -34.3 -16.3% Dec 31, 2022
Q3 2022 173 -44.5 -20.4% Sep 30, 2022
Q2 2022 181 -26.7 -12.8% Jun 30, 2022
Q1 2022 198 +13.2 +7.16% Mar 31, 2022
Q4 2021 210 +40.4 +23.8% Dec 31, 2021
Q3 2021 218 +57.7 +36% Sep 30, 2021
Q2 2021 208 +11.4 +5.81% Jun 30, 2021
Q1 2021 185 -78.1 -29.7% Mar 31, 2021
Q4 2020 170 -157 -48% Dec 31, 2020
Q3 2020 160 -212 -56.9% Sep 30, 2020
Q2 2020 196 -100 -33.8% Jun 30, 2020
Q1 2020 263 +29.1 +12.5% Mar 31, 2020
Q4 2019 327 +107 +48.6% Dec 31, 2019
Q3 2019 372 +120 +47.5% Sep 30, 2019
Q2 2019 297 -43.9 -12.9% Jun 30, 2019
Q1 2019 234 -300 -56.2% Mar 31, 2019
Q4 2018 220 -533 -70.8% Dec 31, 2018
Q3 2018 252 -176 -41.1% Sep 30, 2018
Q2 2018 341 +147 +76.2% Jun 30, 2018
Q1 2018 533 +466 +696% Mar 31, 2018
Q4 2017 753 +719 +2111% Dec 31, 2017
Q3 2017 428 +401 +1488% Sep 30, 2017
Q2 2017 193 +174 +917% Jun 30, 2017
Q1 2017 67 +48.8 +269% Mar 31, 2017
Q4 2016 34.1 +21.6 +173% Dec 31, 2016
Q3 2016 27 +11 +69.1% Sep 30, 2016
Q2 2016 19 Jun 30, 2016
Q1 2016 18.2 Mar 31, 2016
Q4 2015 12.5 Dec 31, 2015
Q3 2015 15.9 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.